TITLE

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

AUTHOR(S)
Kupsch, A.; Sautter, J.; Götz, M. E.; Breithaupt, W.; Schwarz, J.; Youdim, M. B. H.; Riederer, P.; Gerlach, M.; Oertel, W. H.
PUB. DATE
September 2001
SOURCE
Journal of Neural Transmission;Sep2001, Vol. 108 Issue 8/9, p985
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to induce parkinsonism in man and non-human primates. Monoamine-oxidase B (MAO-B) has been reported to be implicated in both MPTP-induced parkinsonism and Parkinson's disease, since selegiline (L-deprenyl), an irreversible MAO-B inhibitor, prevents MPTP-induced neurotoxicity in numerous species including mice, goldfish and drosophyla. However, one disadvantage of this substance relates to its metabolism to (-)-methamphetamine and (-)-amphetamine. Rasagiline (R-(+)-N-propyl-1-aminoindane) is a novel irrevesible MAO-B-inhibitor, which is not metabolized to metamphetamine and/or amphetamine. The present study compared the effects of high doses of selegiline and rasagiline (10 mg/kg body weight s.c.) on MPTP-induced dopaminergic neurotoxicity in a non-human primate (Callithrix jacchus) model of PD. Groups of four monkeys were assigned to the following six experimental groups: Group I: Saline, Group II: Selegiline/Saline, Group III: Rasagiline/Saline, Group IV: MPTP/Saline, Group V: Rasagiline/MPTP, Group VI: Selegiline/MPTP. Daily treatment with MAO-B-inhibitors (either rasagiline or selegiline, 10 mg/kg body weight s.c.) was initiated four days prior to MPTP-exposure (MPTP-HCl, 2 mg/kg body weight subcutaneously, separated by an interval of 24 hours for a total of four days) and was continued until the end of the experiment, i.e. 7 days after the cessation of the MPTP-injections, when animals were sacrificed. MPTP-treatment caused distinct behavioural, histological, and biochemical alterations: 1. significant reduction of motor activity assessed by clinical rating and by computerized locomotor activity measurements; 2. substantial loss (approx. 40%) of dopaminergic (tyrosine-hydroxylase-positive) cells in the substantia nigra, pars compacta; and 3. putaminal dopamine depletion of 98% and its metabolites DOPAC (88%) and HVA (96%). Treatment with either rasagiline or selegiline markedly attenuated the neurotoxic effects of MPTP at the behavioural, histological, and at the biochemical levels. There were no significant differences between rasagiline/MPTP and selegiline/MPTP-treated animals in respect to signs of motor impairment, the number of dopaminergic cells in the substantia nigra, and striatal dopamine levels. As expected, both inhibitors decreased the metabolism of dopamine, leading to reduced levels of HVA and DOPAC (by >95% and 45% respectively). In conclusion, rasagiline and selegiline at the dosages employed equally protect against MPTP-toxicity in the common marmoset, suggesting that selegiline-derived metabolites are not important for the neuroprotective effects of high dose selegiline in the non-human MPTP-primate model in the experimental design employed. However, unexpectedly, high dose treatment with both MAO-inhibitors caused a decrease of the cell sizes of nigral tyrosine hydroxylase positive neurons. It remains to be determined, if this histological observation represents potential adverse effects of high dose treatment with monoamine oxidase inhibitors.
ACCESSION #
15394865

 

Related Articles

  • Benefits and Risks of Parkinson's Disease Drugs. Shaughnessy, Allen F. // American Family Physician;1/1/2005, Vol. 71 Issue 1, p144 

    Focuses on a study which concerned the benefits and risks of using monoamine oxidase type B inhibitors in patients with Parkinson's disease. Definition of patients with early Parkinson's disease; Motive for evaluating selegiline; Implication of treatment with a monoamine oxidase type B...

  • Many Researchers, Few Clinicians, Using Drug That May Slow, Even Prevent, Parkinson's. Cotton, Paul // JAMA: Journal of the American Medical Association;9/5/90, Vol. 264 Issue 9, p1083 

    Deals with a study which examined whether deprenyl can slow the progression of Parkinson's disease. Mechanisms of action of deprenyl; Impact on patient; Issue on the price difference of the drug in the U.S. and other countries.

  • The One Minute Counselor.  // Pharmacy Today;Jun2008, Vol. 14 Issue 6, p27 

    The article offers tips and medication for the treatment of Parkinson's disease (PD) in the U.S. There exists many medications for the treatment of PD but if these are not properly administered, it has it own adverse effects including selective monoamine oxidase (MAO)-B inhibitors, selegiline...

  • Selegiline: Mono/combination therapy effective for Parkinson's.  // Geriatrics;Aug1990, Vol. 45 Issue 8, p19 

    The article reports that combination therapy with selegiline (Eldepryl) and levodopa (Dopar, Larodopa) appears to be an effective anti-Parkinson's regimen for patients with moderate to advanced disease. Evaluation of 21 patients treated with 10 to 20 mg selegiline alone for stage I and II...

  • Rasagiline: A Viewpoint by Wolfgang H. Oertel. Oertel, Wolfgang H. // Drugs & Aging;2005, Vol. 22 Issue 1, p93 

    The article presents views of a neurologist about rasagiline drug and its therapeutic use. Rasagiline is a selective, irreversible inhibitor of monoamine-oxidase type B (MAO-B) which has undergone an extensive clinical development program for use in the treatment of Parkinson's disease. Unlike...

  • New hope for Parkinson's disease progression delay. Hughes, Bethan // Nature Reviews Drug Discovery;Oct2008, Vol. 7 Issue 10, p791 

    The article discusses the findings of a study which examines whether resagiline can slow down the progression of Parkinson's disease (PD). It explores the preclinical and clinical evidence which suggests that rasagiline, a selective, irreversible monoamine oxidase B inhibitor, might slow down PD...

  • New Parkinson's drug given FDA nod.  // Drug Topics;7/10/2006, Vol. 150 Issue 13, p8 

    The article reports that Zelapar tablet was approved by Food and Drug Administration(FDA) to treat Parkinson's disease in the U.S. Zelapar tablets from Valeant Pharmaceuticals International contain selegiline, an active hydrochloride medicine. It is a monoamine oxidase-B inhibitor which prevents...

  • Pharmacological Aspects of (-)-Deprenyl. Magyar, K.; Palfi, M.; Tabi, T.; Kalasz, H.; Szerrdend, B.; Sz�ko, E. // Current Medicinal Chemistry;Aug2004, Vol. 11 Issue 15, p2017 

    Deprenyl, the selective irreversible inhibitor of monoamine oxidase-B (MAO-B), has been synthesised as a potential antidepressant, however, due to its dopamine potentiating capacity, became a registered drug in the treatment of Parkinson's disease. Deprenyl possesses a wide range of...

  • Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Heinonen, E.H.; Myllylä, V.; Myllylä, V // Drug Safety;Jul1998, Vol. 19 Issue 1, p11 

    Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease. As the first MAO-B inhibitor approved for the treatment of Parkinson's disease, concerns were raised about the safety of the drug based on the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics